

Quentin Bayard

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2045565/quentin-bayard-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15
papers

469
citations

8
h-index

16
g-index

16
ext. papers

771
ext. citations

11.8
avg, IF

3.13
L-index

#	Paper	IF	Citations
15	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study.. <i>Lancet Oncology, The</i> , 2022 , 23, 161-171	21.7	1
14	Structure, Dynamics, and Impact of Replication Stress-Induced Structural Variants in Hepatocellular Carcinoma.. <i>Cancer Research</i> , 2022 , 82, 1470-1481	10.1	
13	Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. <i>Cancer Discovery</i> , 2021 , 11, 2524-2543	24.4	4
12	Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. <i>Genome Medicine</i> , 2021 , 13, 113	14.4	7
11	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. <i>Journal of Hepatology</i> , 2021 , 74, 1155-1166	13.4	11
10	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. <i>Hepatology</i> , 2021 , 74, 816-834	11.2	7
9	Recurrent chromosomal rearrangements of , and activating JAK/STAT pathway in inflammatory hepatocellular adenomas. <i>Gut</i> , 2020 , 69, 1667-1676	19.2	8
8	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. <i>Journal of Hepatology</i> , 2020 , 72, 924-936	13.4	18
7	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , 2020 , 71, 164-182	11.2	62
6	Adeno-associated virus in the liver: natural history and consequences in tumour development. <i>Gut</i> , 2020 , 69, 737-747	19.2	36
5	High Impact: The Role of Promiscuous Binding Sites in Polypharmacology. <i>Molecules</i> , 2019 , 24,	4.8	3
4	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. <i>Gastroenterology</i> , 2019 , 157, 760-776	13.3	77
3	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. <i>Nature Communications</i> , 2018 , 9, 5235	17.4	73
2	Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer. <i>Bioinformatics</i> , 2018 , 34, 3380-3381	7.2	26
1	Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. <i>Nature Communications</i> , 2017 , 8, 1315	17.4	135